Related Experiment Videos
Therapeutic efficacy of flupenthixol decanoate in schizoaffective disorder: a clinical evaluation
Abstract:
The present open study was undertaken to evaluate the therapeutic efficacy and side-effects of flupenthixol, a thioxanthene derivative in the treatment of schizoaffective psychosis. A total of twenty in-patients, selected according to specific research criteria were treated with flupenthixol (20 mg to 60 mg i.m. q.2.weeks) for a period of 6 months. During the course of the study, a detailed battery of psychiatric rating scales was completed prior to the commencement of the treatment and at regular intervals thereafter. Additionally, detailed physical examinations and laboratory tests were also carried out at regular intervals. Results show that fifteen patients improved significantly, two patients remained unchanged while three patients deteriorated and were discontinued. Adverse effects were minimal and limited to tremor and akathisia. The present study highlights the usefulness of flupenthixol as a monotherapy in the management of schizoaffective psychosis.
Insights
Flupenthixol, a thioxanthene derivative, effectively treated schizoaffective psychosis in an open study. Most patients showed significant improvement with minimal adverse effects, highlighting its monotherapy potential.
Area of Science:
- Psychiatry
- Pharmacology
Background:
- Schizoaffective psychosis is a complex mental disorder requiring effective treatment options.
- Thioxanthene derivatives offer a potential therapeutic avenue for psychosis management.
Purpose of the Study:
- To evaluate the therapeutic efficacy of flupenthixol in treating schizoaffective psychosis.
- To assess the safety and side-effect profile of flupenthixol during treatment.
Main Methods:
- An open study involving twenty in-patients diagnosed with schizoaffective psychosis.
- Treatment with flupenthixol (20-60 mg intramuscularly every two weeks) for six months.
- Utilized psychiatric rating scales, physical examinations, and laboratory tests for assessment.
Main Results:
- Fifteen out of twenty patients demonstrated significant clinical improvement.
- Two patients showed no change in condition, and three were discontinued due to deterioration.
- Adverse effects were minimal, primarily consisting of tremor and akathisia.
Conclusions:
- Flupenthixol demonstrates significant therapeutic efficacy in managing schizoaffective psychosis.
- The medication is well-tolerated, with a low incidence of adverse effects.
- Flupenthixol is a viable monotherapy option for schizoaffective psychosis.